321 related articles for article (PubMed ID: 17876014)
1. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
[TBL] [Abstract][Full Text] [Related]
2. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
3. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ravaud A; Barrios CH; Alekseev B; Tay MH; Agarwala SS; Yalcin S; Lin CC; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau AL; Melichar B
Ann Oncol; 2015 Jul; 26(7):1378-84. PubMed ID: 25851632
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Summers J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Scagliotti GV; Krzakowski M; Szczesna A; Strausz J; Makhson A; Reck M; Wierzbicki RF; Albert I; Thomas M; Miziara JE; Papai ZS; Karaseva N; Thongprasert S; Portulas ED; von Pawel J; Zhang K; Selaru P; Tye L; Chao RC; Govindan R
J Clin Oncol; 2012 Jun; 30(17):2070-8. PubMed ID: 22564989
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
[TBL] [Abstract][Full Text] [Related]
13. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
Jonasch E; Wood CG; Matin SF; Tu SM; Pagliaro LC; Corn PG; Aparicio A; Tamboli P; Millikan RE; Wang X; Araujo JC; Arap W; Tannir N
J Clin Oncol; 2009 Sep; 27(25):4076-81. PubMed ID: 19636008
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
19. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L
Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767
[TBL] [Abstract][Full Text] [Related]
20. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
